Guard Therapeutics International AB (publ) (STO:GUARD)

Market Cap	31.06M -90.1%
Revenue (ttm)	n/a
Net Income	-80.99M
EPS	n/a
Shares Out	20.17M
PE Ratio	n/a
Forward PE	0.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	617,753
Open	1.920
Previous Close	1.398
Day's Range	1.350 - 2.140
52-Week Range	0.881 - 27.000
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About STO:GUARD

Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. The company’s pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to treat Sepsis. It also develops GTZ peptides, a modified A1M-derived peptides which is in preclinical studies for the treatment of CKD and diabet...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 12
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GUARD